Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

N/ANot Yet RecruitingNCT07555301

Waid City Hospital, Zurich50 enrolled

Overview

An observational study tracking the clinical course of patients with IgA nephropathy.

The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.

Study Type

OBSERVATIONAL

Enrollment

Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * IgA Nephropathy, Use of Sparsentan Exclusion Criteria: * age \< 18y

Stadtspital Zurich

Zurich, Canton of Zurich, Switzerland

Change of Albuminuria

What is the impact of sparsentan on Albuminuria

Time frame: 36 months

Andi Schleich

CONTACT

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.